Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

The authors reported that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the Plk1 inhibitor onvansertib, synergized with abiraterone in vitro and in vivo to kill a subset of cancer cells from a wide variety of tumor types in an androgen-independent manner.